Associate Professor, Radiation Medicine and Applied Sciences; University of California, San Diego
Radiation Oncology
Dr. James J. Urbanic, MD
|
|
Give Review
James Urbanic practices Radiation Oncology. He went to medical school at Medical University of South Carolina College of Medicine. He has 7 awards "CMS Meaningful Use Stage 1 Certification", "ASCO Cancer Foundation Young Investigator Award", "American Brachytherapy Society HDR Brachytherapy Fellowship", "RSNA Roentgen Resident/Fellow Research Award", "Presidential Scholar", "Alpha Omega Alpha Honor Medical Society" and "Eugene F. Moran Award". Dr. James J. Urbanic is a published doctor. He has 32 papers published. The most current publication "A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Canc..." He accepts all Medicare patients.
Publications
- A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Canc...
- Prophylactic cranial irradiation in elderly patients with small cell lung Cancer: Findings from a North Central Cancer Treatment Group pooled analysis.
- Erratum to: Local control and toxicity outcomes in brainstem metastases treated with single fraction radiosurgery: is there a volume threshold for toxicity?
- Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment.
- Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung Cancer (NSCLC).
- Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non-Small-Cell Lung C...
- Local control and toxicity outcomes in brainstem metastases treated with single fraction radiosurgery: is there a volume threshold for toxicity?
- A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy.
- Predictors of pulmonary toxicity in limited stage small cell lung Cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherap...
- Tumor Histology Predicts Patterns of Failure and Survival in Patients with Brain Metastases from Lung Cancer Treated with Gamma Knife Radiosurgery.
- A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Dai...
- Breast Cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery.
- A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung Cancer.
- Clinical outcomes of brain metastases treated with Gamma Knife radiosurgery with 3.0 T versus 1.5 T MRI-based treatment planning: have we finally optimised detection ...
- The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery.
- Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung Cancer.
- Toxicity of Gamma Knife Radiosurgery in the Treatment of Intracranial Tumors in Patients with Collagen Vascular Diseases or Multiple Sclerosis.
- High cyclin D3 expression confers erlotinib resistance in aerodigestive tract Cancer.
- Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis.
- "The best-laid plans ... often go awry ...".
- Radiation safety issues with positron-emission/computed tomography simulation for stereotactic body radiation therapy.
- Small cell lung Cancer: have we made any progress over the last 25 years?
- A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
- Confidence intervals and survival estimates: a systematic review of 3 oncology journals.
- Update on brachytherapy in localized prostate Cancer: the importance of dosimetry.
- Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung Cancer: a retrospective analysis.
- Docetaxel followed by gemcitabine and irinotecan in solid tumors.
- Beyond pancreatic Cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
- Could it be that less is more?
- Trends in the outcomes for patients with limited stage small cell lung Cancer: An analysis of the Surveillance, Epidemiology, and End Results database.
- Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate Cancer after low-dose-rate prostate brachytherapy al...
Schools
Medical University of South Carolina
Conditions Treated
- Pituitary Gland Cancer
Doctors Specialties
- Radiation Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Power Select HMO
- Blue Card PPO
- Blue Cross Blue Shield of California PPO
- Select Plus HMO
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Medicare Advantage PFFS
- WholeCare Network HMO
- HealthSmart
- Choice Care PPO
- MedCost PPO
- MedHealthInsurance
- Medicaid
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
- Universal American
Awards
- CMS Meaningful Use Stage 1 Certification
- ASCO Cancer Foundation Young Investigator Award
- American Brachytherapy Society HDR Brachytherapy Fellowship
- RSNA Roentgen Resident/Fellow Research Award
- Presidential Scholar
- Alpha Omega Alpha Honor Medical Society
- Eugene F. Moran Award
Education
-
Wake Forest University -
Medical University of South Carolina College of Medicine
Hospital
-
UC San Diego Health
Drug Facts
| NPI NUMBER | 1164607875 | |
| NPPES Provider LastName | URBANIC | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 920242477 | |
| NPPES Provider State | CA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 150.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 14.67 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164607875 |
| Last Name Of The Provider | URBANIC |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Mary A. Rose, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick W. Linson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eva Lean, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David W. Hodgens, MD |
|
Dr. Norbert J. Kased, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jean M. Mefferd, MD
This Doctor is OpenDoctor Recommended.
|